Synthetic carbohydrate-based anticancer vaccines: The Memorial Sloan-Kettering experience Review uri icon


MeSH Major

  • Antigens, Tumor-Associated, Carbohydrate
  • Cancer Vaccines
  • Immunotherapy
  • Neoplasms


  • Malignantly transformed cells can express aberrant cell surface glycosylation patterns, which serve to distinguish them from normal cells. This phenotype provides an opportunity for the development of carbohydrate-based vaccines for cancer immunotherapy. Synthetic carbohydrate-based vaccines, properly introduced through vaccination of a subject with a suitable construct, should be recognized by the immune system. Antibodies induced against these carbohydrate antigens could then participate in the eradication of carbohydrate-displaying tumor cells. Advances in carbohydrate synthetic capabilities have allowed us to efficiently prepare a range of complex, synthetic anticancer vaccine candidates. We describe herein the progression of our longstanding carbohydrate-based anticancer vaccine program, which is now at the threshold of clinical evaluation in several contexts. Our carbohydrate-based anticancer vaccine program has evolved through a number of stages: monomeric vaccines, monomeric clustered vaccines, unimolecular multi-antigenic vaccines and dual-acting vaccines. This account will focus on our recently developed unimolecular multi-antigenic constructs and potential dual-acting constructs, which contain clusters of both carbohydrate and peptide epitopes.

publication date

  • October 2009



  • Review



  • eng

PubMed Central ID

  • PMC3063993

Digital Object Identifier (DOI)

  • 10.1586/erv.09.95

PubMed ID

  • 19803761

Additional Document Info

start page

  • 1399

end page

  • 413


  • 8


  • 10